References
1. Ferlay J., Colombet M., Soerjomataram I., Mathers C. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods // Int. J. Cancer. 2018 Oct 23. doi: 10.1002/ijc.31937. PubMed PMID: 30350310.
2. American Cancer Society. Cancer Facts and Figures 2019. Global Headquarters. Atlanta : American Cancer Society Inc., 2019. URL: www.cancer.org/
3. Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow: FGBU "MNIOI im. P.A. Gertsena" Minzdrava Rossii, 2018. 250 p. (in Russian)
4. Davydov M.I., Axel E.M. Statistics of malignant neoplasms in Russia and the CIS countries in 2012 Moscow: IG RONTS, 2014. 175 p. (in Russian)
5. Lupia M, Cavallaro U. Ovarian cancer stem cells: still an elusive entity? Mol Cancer. 2017; 16 (1): 64. URL: https://doi.org/10.1186/s12943-017-0638-3 .
6. Ahmed N., Abubaker K., Findlay J., et al. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem. 2013; 114 (1): 21-34.
7. Walters Haygood C.L., Arend R.C., Straughn J.M., et al. Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? World J Stem Cells. 2014; 6 (4): 441-7.
8. Kipps E., Tan D.S., Kaye S.B. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013; 13 (4): 273-82.
9. Mo L., Pospichalova V., Huang Z. Ascites increases expression/ function of multidrug resistance proteins in ovarian cancer cell. PloS One. 2015; 10 (7). doi. 10.1371/journal.pone.0131579.
10. Ahmed N., Abubaker K., Findlay J.K. Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets. Mol Aspects Med. 2013; 39: 110-25. doi: 10.1016/j.mam.2013.06.002.
11. Ricci F., Guffanti F., Damia G., et al. Ovarian cancer recurrence: role of ovarian stem cells and epithelial-to-mesenchymal transition. J Cancer Sci Ther. 2014; 6: 298-305. doi: 10.4172/1948-5956.1000284.
12. Ottevanger P.B. Ovarian cancer stem cells more questions than answers. Semin Cancer Biol. 2017; 14: 67-71.
13. Foster R., Buckanovich R.J., Rueda B.R. Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett. 2013; 338 (1): 147-57.
14. Zhan Q., Wang C., Ngai S. Ovarian cancer stem cells: a new target for cancer therapy // Biomed. Res. Int. 2013. Vol. 2013. Article ID 916819.
15. Kwon M.J., Shin Y.K. Regulation of ovarian cancer stem cells or tumor-initiating cells. Int J Mol Sci. 2013; 14: 6624-48.
16. Banerjee S., Kong D., Wang Z., et al. Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinicio Mutat. Res. 2011; 728: 47-66.
17. Gu J.W., Makey K.L., Tucker K.B., et al. EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1a and NFkB, and VEGF expression. Vasc Cell. 2013; 5 (1): 9. doi: 10.1186/2045-824X-5-9.
18. Khan N., Mukhtar H. Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett. 2008; 269 (2): 269-80.
19. Johnson R., Bryant S., Huntley A.L. Green tea and green tea catechin extracts: an overview of the clinical evidence. Maturitas. 2012; 73 (4): 280-7.
20. Kandala P.K., Srivastava S.K. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT 3) // BMC Med. 2012. Vol. 10. P. 9.
21. Kandala P.K., Srivastava S.K. DIMming ovarian cancer growth // Curr. Drug Targets. 2012. Vol. 13. P. 1869-1875.
22. Kandala P.K., Srivastava S.K. Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling glucose regulatory protein 78 and AMPK. Oncotarget. 2012; 3 (4): 435-49.
23. Zou M., Xu C., Li H. 3,3'-Diindolylmethane suppresses ovarian cancer cell viability and metastasis and enhances chemotherapy sensitivity via STAT3 and Akt signaling in vitro and in vivo. Arch Biochem Biophys. 2018 July. doi: 10.1016/j.abb.2018.07.002.
24. Trudel D., Labbe D.P., Bairati I., et al.Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies. Gynecol Oncol. 2012; 126 (3): 91-8.
25. Chen D., Banerjee S., Cui1 Q.C., et al. Activation of AMP-activated protein kinase by 3,3'-diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo. PLoS One. 2012; 7 (10). Article ID e47186.
26. Semov A., Iourtchenco L., Liu L.F., et al. Diindolylmethane (DIM) selectively inhibits cancer stem cells. Biochem BiophysRes Commun. 2012; 424: 45-51.
27. Gen R.-Y., Li H.-B., Si Z.-Q., et al. Absorption, metabolism, anticancer effect and molecular targets of epigallocatechin gallate (EGCG): an updated review. Crit Rev Food Sci Nutr. 2018; 58 (6): 924-41.
28. Kumazoe M., Takai M., Hiroi S., et al. PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma. Sci Rep. 2017; 7: 1917. doi: 10.1038/s41598-017-02162-9.
29. Rady I., Mohamed H., Rady M., et al.Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea. Egypt J Basic Appl Sci. 2018; 5: 1-23.
30. Toden S., Tran H.M., Tovar-Camargo O.A., et al Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget. 2016; 7 (13): 16 158-71.